Highlights from TASLC 2025 International Symposium by Hidehito Horinouchi
The Taiwan Association for the Study of Lung Cancer (TASLC) 2025 International Symposiam was held from 11-12 January, 2025.
The Taiwan Association for the Study of Lung Cancer (TASLC) is a professional organization dedicated to promoting research, education, and collaboration in the field of lung cancer within Taiwan. The association aims to enhance the understanding of lung cancer through various initiatives, including organizing conferences, workshops, and seminars that bring together healthcare professionals, researchers, and industry experts.
TASLC focuses on advancing knowledge about lung cancer prevention, diagnosis, treatment, and management. It also plays a crucial role in advocating for policies that support lung cancer research and patient care in Taiwan. By fostering collaboration among stakeholders in the healthcare community, TASLC seeks to improve outcomes for lung cancer patients and contribute to global efforts in combating this disease.
Hidehito Horinouchi is the Assistant Chief of the National Cancer Center Hospital. He also serves as the Secretary General of the Lung Cancer Study Group, Japan Clinical Oncology Group, and the Deputy Chief of the Center for Education and Professional Career Development at the National Cancer Center Hospital.
He specializes in multimodal treatment strategies, including medical, surgical, and radiation oncology, for patients with thoracic malignancies.
Hidehito Horinouchi shared his insights from TASLC 2025:
TASLC25 International Symposium:
“Taiwan Association for the Study of Lung Cancer
TASLC25 International Symposium
Chair: Prof. James Yang
Faculties”
”Opening TASLC25 2nd day
TaiwanAssociation for the Study of Lung Cancer
Dr. Gee-Chen Chang.”
“Kicking off 2nd day
TASLC
Experience of amivantamab for EGFR mutated NSCLC.”
IASLC Lung Cancer Staging update and future perspective
“Taiwan Association for the Study of Lung Cancer
IASLC Lung Cancer Staging update and future perspective
Dr. Young Tae Kim, Chair, Lung Domain of SPFG (Staging and Prognostic Factors Group).”
Case presentation: Lung Cancer Staging
“Taiwan Association for the Study of Lung Cancer
Case presentation: Lung Cancer Staging
Dr. Pei-Hsing Chen.”
“Taiwan Association for the Study of Lung Cancer
Is the current staging system sufficient?
Dialogue of the GIANTS.”
Treatment for stage I-III NSCLC:
“Taiwan Association for the Study of Lung Cancer
Treatment for stage I-III NSCLC.”
Case presentation: Early stage NSCLC:
“Taiwan Association for the Study of Lung Cancer
Case presentation: Early stage NSCLC
Dr. Chi-Lu Chiang.”
Neoadjuvant and adjuvant treatment:
”Taiwan Association for the Study of Lung Cancer
Neoadjuvant and adjuvant treatment
Panelists: Martin Reck, Karen Kelly, Dr. Young Tae Kim , Tetsuya Mitsudomi, Dr. Chao-Hua Chiu”
“Taiwan Association for the Study of Lung Cancer
Stage III/IV NSCLC looking forward to long term control
Dr. James CH Yang.”
Case presentation: Long term control and survival:
”Taiwan Association for the Study of Lung Cancer
Case presentation: Long term control and survival
Dr. Derek De-Rui Huang.”
Treatment of stage III/IV NSCLC patients:
“Taiwan Association for the Study of Lung Cancer
Treatment of stage III/IV NSCLC patients aiming for CURE
Panelists – Dr. James CH Yang, David Gandara Fred Hirsch, Karen Kelly, Peters Solange.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023